Artelo Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. The company is headquartered in La Jolla, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-7.44M |
| Operating Margin | 0.00% |
| Return on Equity | -367.70% |
| Return on Assets | -91.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.62 |
| Price-to-Book | 0.53 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 1.22 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $3.49M |
| Float | $2.17M |
| % Insiders | 2.47% |
| % Institutions | 8.10% |
Volatility is currently expanding
Osteoarthritic Pain Model Results Further Validate FABP5 as a Novel Therapeutic Target in Pain Management Osteoarthritic Pain Model Results Further Validate FABP5 as a Novel Therapeutic Target in Pain Management
Every proxy submitted helps establish the quorum needed to conduct the Company's Annual Meeting, regardless of how shareholders choose to vote Every proxy submitted helps establish the quorum needed to conduct the Company's Annual Meeting, regardless of how shareholders choose to vote
Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer
The nonclinical study conducted at Stony Brook University adds to substantial evidence of activity across multiple animal models of neuropathic pain The nonclinical study conducted at Stony Brook University adds to substantial evidence of activity across multiple animal models of neuropathic pain
Multi-omics analyses identifies linoleic acid as a critical fatty acid which is modulated by ART26.12 Multi-omics analyses identifies linoleic acid as a critical fatty acid which is modulated by ART26.12
First-in-Human Results Demonstrate Favorable Safety and Pharmacokinetics Profile AI Aided Target Engagement Research Advancing Development of Novel Biomarkers SOLANA BEACH, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced two presentations of clinical and translational research findings supporting the development of ART26.12, the Company's proprietary selective fatty acid binding protein 5 (FABP5) inhibitor, at the International Cannabinoid Research Society (ICRS) 2026 Annual Symposium.
Artelo's lead medicinal chemist reveals findings at the Royal Society of Chemistry-BMCS/DMDG Medicinal Chemistry Conference in London Artelo's lead medicinal chemist reveals findings at the Royal Society of Chemistry-BMCS/DMDG Medicinal Chemistry Conference in London
SOLANA BEACH, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today provided a business update and announced its financial and operational results for the quarter ended March 31, 2026, and outlined upcoming milestones across its portfolio.
SOLANA BEACH, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced details of a strategic partnership with BioAI company ScienceMachine to accelerate the development of its fatty acid-binding protein 5 (FABP5) inhibitor platform. ScienceMachine's platform, which leverages cutting-edge AI agent technology, is built to interrogate large biological datasets in a fraction of the time and cost of traditional methods.
Demonstrates ART26.12's Differentiated Profile as a Promising Pain Treatment Ahead of Planned Multiple Ascending Dose Study This Year
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ARTL and any ticker you trade — then tracks every position and per-strategy win rate.
